- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Sal Patel, JD: How Sandoz v Amgen Changed the Biosimilars Landscape
Sal Patel, JD, partner at Schiff Hardin, LLP, explains how the Supreme Court's 2017 ruling in Sandoz v Amgen changed the biosimilars landscape.
Transcript
How has last year’s Supreme Court ruling in Sandoz v Amgen changed the biosimilars landscape?
Well, it changes the biosimilar landscape in that now, biosimilar developers can go ahead and file declaratory judgment actions. They don’t need to participate in that long and tortuous patent dance that was required. I think it makes it a little bit easier for biosimilar developers.
Newsletter
Where clinical, regulatory, and economic perspectives converge—sign up for Center for Biosimilars® emails to get expert insights on emerging treatment paradigms, biosimilar policy, and real-world outcomes that shape patient care.
